Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pliant Therapeutics, Inc.

1.58
+0.12008.22%
Post-market: 1.610.0300+1.90%16:58 EDT
Volume:1.48M
Turnover:2.32M
Market Cap:96.99M
PE:-0.44
High:1.65
Open:1.45
Low:1.45
Close:1.46
Loading ...

RBC Cuts Price Target on Pliant Therapeutics to $3 From $4, Keeps Sector Perform, Speculative Risk

MT Newswires Live
·
04 Mar

RBC Capital Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX)

TIPRANKS
·
04 Mar

Wells Fargo Sticks to Its Hold Rating for Pliant Therapeutics (PLRX)

TIPRANKS
·
04 Mar

Pliant Therapeutics Cut to Market Perform From Outperform by Leerink Partners

Dow Jones
·
04 Mar

Pliant Therapeutics Q4 2024 GAAP EPS $(0.82) Beats $(0.98) Estimate

Benzinga
·
04 Mar

BRIEF-Pliant Therapeutics Q4 Net Income USD -49.732 Million

Reuters
·
04 Mar

Sector Update: Health Care Stocks Rise Monday Afternoon

MT Newswires Live
·
04 Mar

BUZZ-Pliant touches record low after scrapping trial of lung-disease drug

Reuters
·
03 Mar

Pliant Therapeutics Ends Phase 2b Trial of Bexotegrast for Idiopathic Pulmonary Fibrosis; Shares Fall

MT Newswires Live
·
03 Mar

BRIEF-Pliant Therapeutics Provides Update On Beacon-IPF

Reuters
·
03 Mar

Pliant Therapeutucs Shares Halted After Bexotegrast Phase 2b Trial Discontinued

Dow Jones
·
03 Mar

Blade Air Mobility Leads The Charge Among 3 US Penny Stocks

Simply Wall St.
·
18 Feb

TD Cowen Keeps Their Buy Rating on Pliant Therapeutics (PLRX)

TIPRANKS
·
18 Feb

Positive Outlook on Pliant Therapeutics Despite Trial Uncertainty

TIPRANKS
·
17 Feb

All You Need to Know About PLIANT THERAPT (PLRX) Rating Upgrade to Buy

Zacks
·
15 Feb

Pliant Therapeutics Price Target Maintained With a $10.00/Share by Needham

Dow Jones
·
14 Feb

Sector Update: Health Care Stocks Mixed Thursday Afternoon

MT Newswires Live
·
14 Feb

Optimistic Buy Recommendation Amid Pliant Therapeutics’ Trial Review and Stock Surge

TIPRANKS
·
14 Feb

Pliant Therapeutics to Assemble Expert Panel to Review BEACON-IPF Trial Data; Shares Jump

MT Newswires Live
·
14 Feb

Pliant Therapeutics Shares Rise After Board Recommendations for Bexotegrast

Dow Jones
·
13 Feb